1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Stonepine Capital Management, LLC Buys BioDelivery Sciences International Inc, Melinta Therapeutics Inc, Oxford Immunotec Global PLC, Sells Amarin Corp PLC, BioSpecifics Technologies Corp, Vanda Pharmaceuticals Inc

Investment company Stonepine Capital Management, LLC buys BioDelivery Sciences International Inc, Melinta Therapeutics Inc, Oxford Immunotec Global PLC, Opiant Pharmaceuticals Inc, Foamix Pharmaceuticals, KalVista Pharmaceuticals Inc, Spero Therapeutics Inc, Molecular Templates Inc, Aldeyra Therapeutics Inc, Xenon Pharmaceuticals Inc, sells Amarin Corp PLC, BioSpecifics Technologies Corp, Vanda Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, Correvio Pharma Corp during the 3-months ended 2018-09-30, according to the most recent filings of the investment company, Stonepine Capital Management, LLC. As of 2018-09-30, Stonepine Capital Management, LLC owns 31 stocks with a total value of $171 million. These are the details of the buys and sells.

For the details of Stonepine Capital Management, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Stonepine+Capital+Management%2C+LLC

These are the top 5 holdings of Stonepine Capital Management, LLC
  1. Apollo Endosurgery Inc (APEN) - 2,577,996 shares, 11.61% of the total portfolio.
  2. Amarin Corp PLC (AMRN) - 1,130,568 shares, 11.56% of the total portfolio. Shares reduced by 80.06%
  3. BioSpecifics Technologies Corp (BSTC) - 285,259 shares, 10.48% of the total portfolio. Shares reduced by 38.16%
  4. BioDelivery Sciences International Inc (BDSI) - 4,311,103 shares, 7.58% of the total portfolio. Shares added by 190.11%
  5. CTI BioPharma Corp (CTIC) - 4,145,459 shares, 5.63% of the total portfolio. Shares added by 2.37%
New Purchase: Oxford Immunotec Global PLC (OXFD)

Stonepine Capital Management, LLC initiated holding in Oxford Immunotec Global PLC. The purchase prices were between $11.87 and $17.64, with an estimated average price of $14.29. The stock is now traded at around $15.31. The impact to a portfolio due to this purchase was 2.3%. The holding were 225,877 shares as of 2018-09-30.

New Purchase: Opiant Pharmaceuticals Inc (OPNT)

Stonepine Capital Management, LLC initiated holding in Opiant Pharmaceuticals Inc. The purchase prices were between $12.89 and $23.43, with an estimated average price of $17.33. The stock is now traded at around $15.77. The impact to a portfolio due to this purchase was 2.09%. The holding were 185,887 shares as of 2018-09-30.

New Purchase: Foamix Pharmaceuticals Ltd (FOMX)

Stonepine Capital Management, LLC initiated holding in Foamix Pharmaceuticals Ltd. The purchase prices were between $5.09 and $6.3, with an estimated average price of $5.71. The stock is now traded at around $3.97. The impact to a portfolio due to this purchase was 1.98%. The holding were 551,078 shares as of 2018-09-30.

New Purchase: KalVista Pharmaceuticals Inc (KALV)

Stonepine Capital Management, LLC initiated holding in KalVista Pharmaceuticals Inc. The purchase prices were between $8 and $22.11, with an estimated average price of $13.49. The stock is now traded at around $23.00. The impact to a portfolio due to this purchase was 1.92%. The holding were 138,100 shares as of 2018-09-30.

New Purchase: Spero Therapeutics Inc (SPRO)

Stonepine Capital Management, LLC initiated holding in Spero Therapeutics Inc. The purchase prices were between $9.69 and $17.79, with an estimated average price of $11.67. The stock is now traded at around $8.26. The impact to a portfolio due to this purchase was 1.5%. The holding were 226,444 shares as of 2018-09-30.

New Purchase: Molecular Templates Inc (MTEM)

Stonepine Capital Management, LLC initiated holding in Molecular Templates Inc. The purchase prices were between $4.07 and $6.25, with an estimated average price of $5.13. The stock is now traded at around $5.08. The impact to a portfolio due to this purchase was 1.28%. The holding were 378,295 shares as of 2018-09-30.

Added: BioDelivery Sciences International Inc (BDSI)

Stonepine Capital Management, LLC added to a holding in BioDelivery Sciences International Inc by 190.11%. The purchase prices were between $2.48 and $3, with an estimated average price of $2.81. The stock is now traded at around $3.59. The impact to a portfolio due to this purchase was 4.97%. The holding were 4,311,103 shares as of 2018-09-30.

Added: Melinta Therapeutics Inc (MLNT)

Stonepine Capital Management, LLC added to a holding in Melinta Therapeutics Inc by 3652.10%. The purchase prices were between $3.9 and $6.75, with an estimated average price of $5.07. The stock is now traded at around $2.35. The impact to a portfolio due to this purchase was 4.73%. The holding were 1,958,595 shares as of 2018-09-30.

Added: Cidara Therapeutics Inc (CDTX)

Stonepine Capital Management, LLC added to a holding in Cidara Therapeutics Inc by 54.20%. The purchase prices were between $3.7 and $5.25, with an estimated average price of $4.42. The stock is now traded at around $3.35. The impact to a portfolio due to this purchase was 0.64%. The holding were 656,148 shares as of 2018-09-30.

Added: Ophthotech Corp (OPHT)

Stonepine Capital Management, LLC added to a holding in Ophthotech Corp by 21.59%. The purchase prices were between $2.31 and $2.83, with an estimated average price of $2.5. The stock is now traded at around $1.81. The impact to a portfolio due to this purchase was 0.61%. The holding were 2,324,782 shares as of 2018-09-30.

Sold Out: Rigel Pharmaceuticals Inc (RIGL)

Stonepine Capital Management, LLC sold out a holding in Rigel Pharmaceuticals Inc. The sale prices were between $2.6 and $3.59, with an estimated average price of $3.01.

Sold Out: ADMA Biologics Inc (ADMA)

Stonepine Capital Management, LLC sold out a holding in ADMA Biologics Inc. The sale prices were between $4.39 and $6.85, with an estimated average price of $5.75.

Sold Out: ACADIA Pharmaceuticals Inc (ACAD)

Stonepine Capital Management, LLC sold out a holding in ACADIA Pharmaceuticals Inc. The sale prices were between $13.03 and $21.81, with an estimated average price of $15.72.

Sold Out: Syndax Pharmaceuticals Inc (SNDX)

Stonepine Capital Management, LLC sold out a holding in Syndax Pharmaceuticals Inc. The sale prices were between $6.33 and $8.08, with an estimated average price of $7.14.

Sold Out: Gemphire Therapeutics Inc (GEMP)

Stonepine Capital Management, LLC sold out a holding in Gemphire Therapeutics Inc. The sale prices were between $1.36 and $8.42, with an estimated average price of $4.23.

Sold Out: Conformis Inc (CFMS)

Stonepine Capital Management, LLC sold out a holding in Conformis Inc. The sale prices were between $0.89 and $1.28, with an estimated average price of $1.09.

Reduced: Amarin Corp PLC (AMRN)

Stonepine Capital Management, LLC reduced to a holding in Amarin Corp PLC by 80.06%. The sale prices were between $2.45 and $16.27, with an estimated average price of $3.75. The stock is now traded at around $17.14. The impact to a portfolio due to this sale was -8.53%. Stonepine Capital Management, LLC still held 1,130,568 shares as of 2018-09-30.

Reduced: BioSpecifics Technologies Corp (BSTC)

Stonepine Capital Management, LLC reduced to a holding in BioSpecifics Technologies Corp by 38.16%. The sale prices were between $44.14 and $61.16, with an estimated average price of $50.96. The stock is now traded at around $59.50. The impact to a portfolio due to this sale was -4.8%. Stonepine Capital Management, LLC still held 285,259 shares as of 2018-09-30.

Reduced: Vanda Pharmaceuticals Inc (VNDA)

Stonepine Capital Management, LLC reduced to a holding in Vanda Pharmaceuticals Inc by 45.9%. The sale prices were between $18.25 and $23, with an estimated average price of $20.38. The stock is now traded at around $23.43. The impact to a portfolio due to this sale was -3.19%. Stonepine Capital Management, LLC still held 324,600 shares as of 2018-09-30.

Reduced: Correvio Pharma Corp (CORV)

Stonepine Capital Management, LLC reduced to a holding in Correvio Pharma Corp by 53.46%. The sale prices were between $3.71 and $5.13, with an estimated average price of $4.4. The stock is now traded at around $3.46. The impact to a portfolio due to this sale was -2.37%. Stonepine Capital Management, LLC still held 898,157 shares as of 2018-09-30.

Reduced: HTG Molecular Diagnostics Inc (HTGM)

Stonepine Capital Management, LLC reduced to a holding in HTG Molecular Diagnostics Inc by 68.29%. The sale prices were between $2.8 and $5.34, with an estimated average price of $3.68. The stock is now traded at around $3.45. The impact to a portfolio due to this sale was -2.29%. Stonepine Capital Management, LLC still held 535,590 shares as of 2018-09-30.

Reduced: Viveve Medical Inc (VIVE)

Stonepine Capital Management, LLC reduced to a holding in Viveve Medical Inc by 32.47%. The sale prices were between $2.02 and $3.51, with an estimated average price of $2.84. The stock is now traded at around $2.18. The impact to a portfolio due to this sale was -2.07%. Stonepine Capital Management, LLC still held 2,599,711 shares as of 2018-09-30.



Here is the complete portfolio of Stonepine Capital Management, LLC. Also check out:

1. Stonepine Capital Management, LLC's Undervalued Stocks
2. Stonepine Capital Management, LLC's Top Growth Companies, and
3. Stonepine Capital Management, LLC's High Yield stocks
4. Stocks that Stonepine Capital Management, LLC keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK